A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT04740814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label Study to Evaluate the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis Using an Electrochemiluminescent Immuno-Assay
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.
Study identification
- NCT ID
- NCT04740814
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 69 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2021 (Actual)
- Primary completion
- Jan 24, 2022 (Actual)
- Completion
- Jun 27, 2022 (Actual)
- Last update posted
- Feb 12, 2024
2021 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ra0138 1009 | Phoenix | Arizona | 85032 | — |
| Ra0138 1002 | Covina | California | 91722 | — |
| Ra0138 1008 | Upland | California | 91786 | — |
| Ra0138 1015 | Palm Harbor | Florida | 34684 | — |
| Ra0138 1004 | Plantation | Florida | 33324 | — |
| Ra0138 1001 | Lexington | Kentucky | 40504 | — |
| Ra0138 1014 | Rockville | Maryland | 20850 | — |
| Ra0138 1005 | Albuquerque | New Mexico | 87102 | — |
| Ra0138 10025 | Duncansville | Pennsylvania | 16635 | — |
| Ra0138 1003 | Duncansville | Pennsylvania | 16635 | — |
| Ra0138 1016 | Memphis | Tennessee | 38119 | — |
| Ra0138 1007 | Austin | Texas | 78731 | — |
| Ra0138 1010 | Dallas | Texas | 75231 | — |
| Ra0138 1011 | Tomball | Texas | 77375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04740814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2024 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04740814 live on ClinicalTrials.gov.